EVISA Glossary on | Contact EVISA | Sitemap | Home   
Search
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).


Supporters of EVISA includes:
Chemocare: Cisplatin

Link http://chemocare.com/chemotherapy/drug-info/cispla
tin.aspx
Elements Platinum
Species Complex
Topic Information - Pharmacy/Pharmacology
Owner Company
Location ----
Language English
Description
Cisplatin is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug.  Cisplatin is classified as an "alkylating agent."   (For more detail, see "How Cisplatin Works" section below).





Events
See the complete list of deadlines!
PittCon 2025
01.03.2025
Boston, Massachusetts
EWCPS 2025: 20th European Winter Conference on Plasma Spectrochemistry
02.03.2025
Berlin, Germany
DGMS 2025: 56. DGMS-Jahrestagung
04.03.2025
Göttingen, Germany
... more Events
News
What's new on EVISA's web site ?
First strontium isotope map of Sub-Saharan Africa is a powerful tool for tracing origins in archaeology and wildlife trafficking
150 Years of Innovation: Shimadzu Corporation to Mark 150th Anniversary with Special Celebrations
X-ray absorption spectroscopy for speciation analysis
Health Risk Assessment of Complex Organoarsenic Species in Food
... more News




Imprint     Disclaimer

© 2003 - 2025 by European Virtual Institute for Speciation Analysis ( EVISA )